Ernexa Therapeutics Inc.
ERNA
$0.29
$0.001.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 73.92% | 95.34% | 43.23% | -23.39% | 6.40% |
| Total Depreciation and Amortization | 1.47% | -84.48% | -90.48% | -87.25% | -85.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 1,139.44% |
| Total Other Non-Cash Items | -27.49% | -101.73% | 127.04% | 525.48% | 58.22% |
| Change in Net Operating Assets | 96.50% | 108.51% | -128.88% | -76.94% | -404.91% |
| Cash from Operations | 67.62% | 79.76% | -12.08% | 44.89% | 23.94% |
| Capital Expenditure | -- | -15.79% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -15.79% | -- | -- | 100.00% |
| Total Debt Issued | -- | -100.00% | -- | 60.14% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -77.63% |
| Cash from Financing | -100.00% | -99.33% | 22,504.55% | 62.74% | -86.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 54.12% | 47.54% | 194.74% | 107.69% | -183.83% |